Document:

Exhibit 10.1

 

EXTENSION AGREEMENT

 

This Extension Agreement, dated June 13,
2019 (the “Agreement”), is entered into by and between Leaping Group Co., Ltd., a Cayman Islands exempted company
with limited liability having an address at 2010 Huaruntiexi Center, Tiexi District, Shenyang, Liaoning Province, People’s
Republic of China (the “Company”), and Boustead Securities, LLC, having an address at 6 Venture, Suite 265,
Irvine, CA 92618 USA (the “Underwriter,” and together with the Company, the “Parties”).

 

WHEREAS, the Company filed with
the U.S. Securities and Exchange Commission a prospectus on March 22, 2019 (the “Prospectus”) with respect to
the proposed initial offering of the ordinary shares of the Company (the “Offering”);

 

WHEREAS, pursuant to the Prospectus,
the Offering may close or terminate, as the case may be, on the earlier of (i) any time after the minimum offering amount of the
ordinary shares of the Company is raised, or (ii) 90 days from the date of the Prospectus, unless extended by the Parties for an
additional 60 days (the “Offering Period”); and

 

WHEREAS, the Parties desire to extend
the Offering Period.

 

NOW, THEREFORE, the Parties hereby
agreed to the following:

 

		1.	The Parties agree to extend the Offering Period for an additional 60 days until August 17, 2019.

 

		2.	This Agreement shall be governed by and construed and enforced in accordance with the laws of the
State of New York, without giving effect to conflict of laws principles thereof. The Company hereby agrees that any action, proceeding
or claim against it arising out of, or relating in any way to this Agreement shall be brought and enforced in the New York Supreme
Court, County of New York, or in the United States District Court for the Southern District of New York, and irrevocably submits
to such jurisdiction, which jurisdiction shall be exclusive. The Company hereby waives any objection to such exclusive jurisdiction
and that such courts represent an inconvenient forum. The Company agrees that the prevailing party(ies) in any such action shall
be entitled to recover from the other party(ies) all of its reasonable attorneys’ fees and expenses relating to such action
or proceeding and/or incurred in connection with the preparation therefor. The Company (on its behalf and, to the extent permitted
by applicable law, on behalf of its shareholders and affiliates) and the Underwriter hereby irrevocably waives, to the fullest
extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this
Agreement or the transactions contemplated hereby.

  

(Signature page follows)

 

     

     

    

 

IN WITNESS WHEREOF, the parties have duly executed this
Agreement as of the date first set forth above.

 

	Leaping Group Co., Ltd. 	 	Boustead Securities, LLC
	 	 	 	 	 	 	 
	By: 	/s/ Tao Jiang	 	By: 	/s/ Keith Moore
	 	Name: 	Tao Jiang	 	 	Name: 	Keith Moore
	 	Title: 	Chief Executive Officer	 	 	Title: 	Chief Executive Officerex_147201.htm

Exhibit 10.1

 

 

THIRD AMENDMENT TO THE CONVERTIBLE PROMISSORY NOTE ISSUED ON SEPTEMBER 17, 2018

 

THIS THIRD AMENDMENT TO THE CONVERTIBLE PROMISSORY NOTE ISSUED ON September 17, 2018, (the “Amendment”) is made effective as of June 11, 2019 (the “Effective Date”), by and between NUO THERAPUETICS, INC., a Delaware corporation (the “Company”), and Auctus Fund, LLC, a Delaware limited liability company (the “Holder”) (each the Company and the Holder a “Party” and collectively the “Parties”).

 

BACKGROUND

 

A.      The Company and Holder are the parties to that certain securities purchase agreement (the “SPA”) dated September 17, 2018, pursuant to which the Company issued to Holder a convertible promissory note on even date in the original principal amount of $175,000.00 (as amended from time to time, the “Note”); and

 

B.       The Parties desire to amend the Note as set forth expressly below.

 

NOW THEREFORE, in consideration of the execution and delivery of the Amendment and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

 

1.     As of the Effective Date of this Amendment, if: (i) no Event of Default (as defined in the Note) (each an “Event of Default”) shall have occurred; (ii) there is no breach of this Amendment; (iii) the Company wires the amount of $5,000 to the Holder in accordance with the wire transfer instructions attached hereto as Exhibit A no later than June 11, 2019 (“Payment Deadline”) (which will not reduce the balance owed under the Note); then: (a) the references to “May 31, 2019” in Sections 1.9(b) and 1.9(c) of the Note, as amended shall be replaced with “July 31, 2019” and (b) the Holder shall refrain from exercising its right to convert the Note until July 31, 2019. In the event that all other noteholders of convertible debt of the Company as of the Effective Date (i) do not also agree in a signed writing to extend the period that Company is permitted to prepay the Company’s other convertible debt by at least an additional 51 days and/or (ii) fail to agree in a signed writing to refrain from exercising their conversion rights under their respective convertible debt by at least an additional 51 days, then this Amendment may be declared null and void at the option of the Holder.

 

2.     Upon the: (i) occurrence of an Event of Default under the Note or (ii) Company’s breach of any provision or representation in this Amendment, then this Amendment may be declared null and void at the option of the Holder.

 

3.     The Maturity Date (as defined in the Note) of the Note shall be extended to July 31, 2019.

 

4.     The principal balance of the Note shall be increased by $20,000 on the Effective Date.

 

5.     This Amendment shall be deemed part of, but shall take precedence over and supersede, any provisions to the contrary contained in the Note. Except as specifically modified hereby, all of the provisions of the Note, which are not in conflict with the terms of this Amendment, shall remain in full force and effect.

 

6.     This Amendment may be executed in any number of counterparts, each of which when so executed and delivered shall be deemed to be an original and all of which together shall be deemed to be one and the same agreement. Any signature transmitted by facsimile, e-mail, or other electronic means shall be deemed to be an original signature.

 

[Signature page to follow]

 

 

IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date first above written.

 

 

	
			Nuo Therapeutics

			 

			By:   /s/ David Jorden

			Name: David E. Jorden

			Title: CEO

				
			Auctus Fund, LLC

			 

			By:   /s/ Lou Posner

			Name: Lou Posner

			Title: Managing Directorex_147202.htm

Exhibit 10.2

 

 

THIRD AMENDMENT TO THE CONVERTIBLE PROMISSORY NOTE ISSUED ON SEPTEMBER 17, 2018

 

THIS THIRD AMENDMENT TO THE CONVERTIBLE PROMISSORY NOTE ISSUED ON September 17, 2018 (the “Amendment”) is made effective as of June 12, 2019 (the “Effective Date”), by and between NUO THERAPUETICS, INC., a Delaware corporation (the “Company”), and EMA Financial, LLC, a Delaware limited liability company (the “Holder”) (each the Company and the Holder a “Party” and collectively the “Parties”).

 

BACKGROUND

 

A.       WHEREAS, The Company and Holder are the parties to that certain securities purchase agreement (the “SPA”) dated September 17, 2018 pursuant to which the Company issued to Holder a convertible note on even date, in the original principal amount of $175,000.00 (as amended from time to time, the “Note”); and

 

B.       WHEREAS, in accordance with the terms of Section 1.8 of the Note, as previously amended, the Company may prepay the Note until May 31, 2019 (the “Prepayment Termination Date”), with no prepayment permitted thereafter; and

 

C.       WHEREAS, the Parties desire to amend the Note as set forth expressly below.

 

NOW THEREFORE, in consideration of the execution and delivery of the Amendment and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

 

1.     As of the Effective Date of this Amendment if: (i) no Event of Default (as defined under the Note) shall have occurred; (ii) there is no breach of any of the terms of this Amendment; (iii) the Company wires the amount of $5,000.00 to the Holder in accordance with the wire transfer instructions attached hereto as Exhibit A no later than end of business day June 11, 2019 (“Payment Deadline”) (which will not reduce the balance owed under the Note); then: (a) the Prepayment Termination Date shall be July 31, 2019, provided that any prepayment of the Note prior to or on this new Prepayment Termination Date shall be subject to the last applicable Prepayment Factor (which is 145% of the outstanding balance of the Note) as set forth in the Note; and (b) the Holder shall refrain from exercising its right to convert the Note until July 31, 2019, provided however, in the event that the Company and all other holders of convertible debt do not as of the date hereof also agree in a signed writing in the same form and substance as the terms contained in this Amendment, specifically, agreeing to extend the period that Company is permitted to prepay its other convertible notes by at least an additional 51 days, and/or the other noteholders fail to agree in a signed writing to refrain from exercising their conversion rights under their respective outstanding convertible notes by at least an additional 51 days then this Amendment shall be null and void at the option of the Holder.

 

2.     Upon the: (i) occurrence of an Event of Default (as defined in the Note), or (ii) Company’s breach of any provision or representation in this Amendment this Amendment shall be null and void at the option of the Holder and the Holder shall automatically, immediately and without further action be entitled to all its rights, privileges, and preferences under the Note.

 

3.     The principal balance of the Note shall be increased by $20,000.00 on the Effective Date.

 

4.     This Amendment shall be deemed part of, but shall take precedence over and supersede any provisions to the contrary contained in the Note. Except as specifically modified hereby, all of the provisions of the Note, which are not in conflict with the terms of this Amendment, shall remain in full force and effect.

 

5.     This Amendment may be executed in any number of counterparts, each of which when so executed and delivered shall be deemed to be an original and all of which together shall be deemed to be one and the same agreement. Any signature transmitted by facsimile, e-mail, or other electronic means shall be deemed to be an original signature.

 

[Signature page to follow]

 

 

IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date first above written.

 

 

	
			Nuo Therapeutics

			 

			By: /s/ David Jorden

			Name: David E. Jorden

			Title: CEO

				
			EMA Financial, LLC

			 

			By: /s/ Felicia Preston

			Name: Felicia Preston

			Title: Director

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00297-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00297-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00297-of-00352.parquet"}]]